FDA Approves Lembaz for Infantile-Onset Niemann-Pick Type C, First Treatment Shown to Extend Survival
FDA approves Lembaz (adrabetadex) for infantile-onset Niemann-Pick type C — the first therapy shown to extend survival in this ultra-rare childhood disorder.